Join Growin Stock Community!

Replimune group, inc.REPL.US Overview

US StockHealthcare
(No presentation for REPL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

REPL AI Insights

REPL Overall Performance

REPL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

REPL Recent Performance

-6.14%

Replimune group, inc.

0.05%

Avg of Sector

-0.31%

S&P500

REPL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

REPL Key Information

REPL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

REPL Profile

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Price of REPL

REPL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

REPL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.81
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.02
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.81
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.02
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is REPL's latest earnings report released?

    The most recent financial report for Replimune group, inc. (REPL) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating REPL's short-term business performance and financial health. For the latest updates on REPL's earnings releases, visit this page regularly.

  • How much debt does REPL have?

    As of the end of the reporting period, Replimune group, inc. (REPL) had total debt of 76.35M, with a debt ratio of 0.23. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does REPL have?

    At the end of the period, Replimune group, inc. (REPL) held Total Cash and Cash Equivalents of 124.66M, accounting for 0.37 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is REPL's EPS continuing to grow?

    According to the past four quarterly reports, Replimune group, inc. (REPL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.77. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of REPL?

    Replimune group, inc. (REPL)'s Free Cash Flow (FCF) for the period is -66.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 25.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of REPL?

    The latest valuation data shows Replimune group, inc. (REPL) has a Price-To-Earnings (PE) ratio of -1.94 and a Price/Earnings-To-Growth (PEG) ratio of 0.22. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.